文献速递眼底病与葡萄膜炎

糖尿病视网膜病变与生活质量:系统综述与荟萃分析

Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

该系统综述与荟萃分析检索MEDLINE、EBSCO、Embase和Web of Science至2022年4月,纳入93篇文章,发现糖尿病视网膜病变患者的视功能相关生活质量随病变存在及严重程度下降,非威胁视力型糖尿病视网膜病变患者VFQ-25综合评分较无糖尿病视网膜病变者低3.8分,威胁视力型糖尿病视网膜病变患者低25.1分;健康相关生活质量与非威胁视力型糖尿病视网膜病变关联弱或无关联,与威胁视力型糖尿病视网膜病变关联强。作者认为在早期和晚期减少糖尿病视网膜病变进展的干预可能改善视功能相关生活质量。

要点

  • 糖尿病视网膜病变患者视功能相关生活质量随病变存在及严重程度下降。
  • 威胁视力型糖尿病视网膜病变患者VFQ-25综合评分较无糖尿病视网膜病变者低25.1分。
  • 健康相关生活质量与非威胁视力型糖尿病视网膜病变关联弱或无关联,与威胁视力型糖尿病视网膜病变关联强。

核心结论

  • 研究发现视功能相关生活质量随糖尿病视网膜病变的存在和严重程度而下降。
  • 作者认为在早期和更晚期减少糖尿病视网膜病变进展的干预可能改善视功能相关生活质量。

研究设计与样本

  • 遵循系统综述与荟萃分析优先报告条目(PRISMA)指南,检索MEDLINE、EBSCO、Embase和Web of Science自建库至2022年4月。
  • 共纳入93篇文章,其中79篇进入荟萃分析,14篇进入叙述性结果。
  • 分析1以无糖尿病视网膜病变参与者为参照组,比较按糖尿病视网膜病变严重程度分组的参与者生活质量评分。
  • 分析2纳入所有糖尿病视网膜病变参与者且有生活质量测量,按糖尿病视网膜病变严重程度分类合并生活质量评分并比较。

主要发现

  • 视功能相关生活质量在54项研究中记录,健康相关生活质量在26项中记录,两者均在13项中记录。
  • 分析1纳入8项研究,包括1138例糖尿病视网膜病变参与者和347例无糖尿病视网膜病变参与者。
  • 与非糖尿病视网膜病变参与者相比,VFQ-25综合评分在非威胁视力型糖尿病视网膜病变者中低3.8分(95%CI,1.0-6.7),在任何糖尿病视网膜病变者中低12.5分(95%CI,8.5-16.5),在威胁视力型糖尿病视网膜病变者中低25.1分(95%CI,22.8-27.2)(趋势P<.001)。
  • 分析2纳入35项研究,包括6351例糖尿病视网膜病变参与者,VFQ-25综合评分合并均值在非威胁视力型糖尿病视网膜病变参与者中为91.8(95%CI,91.0-92.7),在任何糖尿病视网膜病变参与者中为77.6(95%CI,76.9-78.3),在威胁视力型糖尿病视网膜病变参与者中为73.2(95%CI,72.6-73.7)(趋势P<.001)。
  • 健康相关生活质量评分与非威胁视力型糖尿病视网膜病变关联弱或无关联,与威胁视力型糖尿病视网膜病变关联强。

关键数值与推荐

  • 视功能相关生活质量最常用量表为美国国立眼科研究所25项视功能问卷(VFQ-25)(n=49),健康相关生活质量最常用量表为简表健康调查(SF)(n=18)。
  • 35项研究报告了VFQ-25综合评分。
  • 分析1中,与非糖尿病视网膜病变参与者相比,VFQ-25综合评分在非威胁视力型糖尿病视网膜病变者中低3.8分(95%CI,1.0-6.7),在任何糖尿病视网膜病变者中低12.5分(95%CI,8.5-16.5),在威胁视力型糖尿病视网膜病变者中低25.1分(95%CI,22.8-27.2)(趋势P<.001)。
  • 分析2中,VFQ-25综合评分合并均值在非威胁视力型糖尿病视网膜病变参与者中为91.8(95%CI,91.0-92.7),在任何糖尿病视网膜病变参与者中为77.6(95%CI,76.9-78.3),在威胁视力型糖尿病视网膜病变参与者中为73.2(95%CI,72.6-73.7)(趋势P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The association between diabetic retinopathy (DR) and quality of life (QoL) has not been thoroughly investigated. OBJECTIVE: To investigate the association between DR and both vision-related QoL (VRQoL) and general health-related QoL (HRQoL). DATA SOURCES: MEDLINE, EBSCO, Embase, and Web of Science were searched from their inception to April 2022. STUDY SELECTION: Studies included adults with DR and a measure of QoL. DATA EXTRACTION AND SYNTHESIS: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Two assumption-free meta-analyses were conducted. Analysis 1 included studies with participants without DR as the referent group to which QoL scores of participants with DR, grouped according to DR severity, were compared. Analysis 2 included all studies with participants with DR and a measure of QoL. QoL scores were pooled within categories of DR severity, and comparisons were made between these categories. MAIN OUTCOME AND MEASURES: QoL measured using HRQoL and VRQoL scales. RESULTS: A total of 93 articles were included: 79 in the meta-analyses and 14 in the narrative results. VRQoL was recorded in 54 studies, HRQoL in 26, and both in 13 studies. The most commonly used scales were the National Eye Institute 25-item Visual Function Questionnaire (VFQ-25) (n = 49) for VRQoL and the Short Form (SF) Health Survey (n = 18) for HRQoL. Thirty-five studies reported VFQ-25 composite scores. Analysis 1 consisted of 8 studies including 1138 participants with DR and 347 participants without DR. Compared with participants without DR, the composite VFQ-25 score was 3.8 (95% CI, 1.0-6.7) points lower in those with non-vision-threatening DR (NVTDR), 12.5 (95% CI, 8.5-16.5) lower in those with any DR, and 25.1 (95% CI, 22.8-27.2) lower in VTDR (P < .001 for trend). Analysis 2 consisted of 35 studies including 6351 participants with DR. The pooled mean VFQ-25 composite score was 91.8 (95% CI, 91.0-92.7) for participants with NVTDR, 77.6 (95% CI, 76.9-78.3) for any DR, and 73.2 (95% CI, 72.6-73.7) for VTDR (P < .001 for trend). HRQoL scores had weak or no associations with NVTDR and strong associations with VTDR. CONCLUSIONS AND RELEVANCE: This study found that VRQoL declined with the presence and severity of DR. Interventions to reduce progression of DR at both early and more advanced stages could improve VRQoL.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zayed MG, Karsan W, Peto T, et al. Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis. JAMA Ophthalmol. 2024. PMID: 38300578. doi:10.1001/jamaophthalmol.2023.6435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。